Comparative efficacy and safety of BCMA-targeted CAR T cells and BiTEs in relapsed/refractory multiple myeloma: a meta-analysis of interventional and real-world studies
HematologiaSobre o estudo
- Desenho
- Metanálise
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- Annals of hematology
- Publicado em
- 9 set 2025
- Citações
- 14
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Comparative efficacy and safety of BCMA-targeted CAR T cells and BiTEs in relapsed/refractory multiple myeloma: a meta-analysis of interventional and real-world studies
Pisanupong Techaapornkun, Waranyoo Rojpalakorn, Nuthchaya Mejun, Asmita Khaniya, Arsa Thammahong, May Soe Thu, Nattiya Hirankarn, Palada Pitakkitnukun
Descritores MeSH
- Immunotherapy, Adoptive
- Antibodies, Bispecific
- B-Cell Maturation Antigen
- Multiple Myeloma
- Receptors, Chimeric Antigen
- Humans
- Treatment Outcome
Veja também
Estudos relacionados
- A systematic review of indirect treatment comparisons among recently approved chimeric antigen receptor T-cell and bispecific antibody therapies for triple-class exposed relapsed/refractory multiple myeloma
- Salvage Therapies After Anti-BCMA CAR-T Failure in Patients With Multiple Myeloma: A Meta-Analysis of Response Rates
- Comparison of CAR T-cell and bispecific antibody as third-line or later-line treatments for multiple myeloma: a meta-analysis
- Impact of Treatment Modality and Route of Administration on Cytokine Release Syndrome in Relapsed or Refractory Multiple Myeloma: A Meta-Analysis
- Eficácia e perfis de toxicidade específicos de anticorpos biespecíficos alvo de GPRC5D versus BCMA em mieloma múltiplo recidivado/refratário: uma meta-análise de ensaios clínicos e estudos no mundo real